Skip to main content
. 2024 Apr 8;25:124. doi: 10.1186/s12882-024-03561-7

Table 4.

Comparison of clinical parameters of patients treated with MP who improved and progressed

improvement progression P value
(n = 49) (n = 8)
Age, years, median (range) 53 (19–74) 65.5 (47–74) 0.0118
Gender, n (%) Male 31 (63) 5 (63) > 0.9999
Female 18 (37) 3 (38)
DM, n (%) 10 (20) 3 (38) 0.3653
BMI, kg/m2, median (range) 22 (17.0–29.6) 22.8 (18.8–28.8) 0.2104
> 25, n (%) 5 (10) 3 (38) 0.0742
Use of MMF as maintenance immunosuppression, n (%) 30 (61) 5 (63) > 0.9999

Time from symptom onset to MP treatment,

days, median (range)

1 (0–5) 2.5 (1–10) 0.0430
Baseline eGFR, ml/min/1.73m2, median (range) 46 (19.2–99.5) 44.45 (18.3–73.5) 0.9451
< 30, n (%) 4 (8) 2 (25) 0.1943
Previous SARS-CoV-2 vaccine, doses, median (range) 4 (2–6) 4 (0–5) 0.8933